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Photodynamic therapy (PDT) is a cancer treatment modality based
on the dye-sensitized photooxydation of biological matter in the
target tissue which is now undergoing clinical trials in several
countries (Foote et al, 1990; Henderson and Dougherty, 1992;
Fisher et al, 1995; Kato, 1996). The actual agent mediating cyto-
toxicity appears to be singlet oxygen (Weishaupt et al, 1976). The
mechanisms involved in PDT tumour destruction are not yet fully
understood. Analysis of the metabolic changes occurring in the
tumour cells in vivo in the host body is a useful method to evaluate
the effects of PDT.
Phosphorus 31 magnetic resonance spectroscopy (31P MRS)
provides a non-invasive analytical method for monitoring levels of
high-energy phosphorus-containing compounds. The use of a
surface coil allows sequential measurement of a tumour in situ in
the same animal. Several investigations have dealt with the meta-
bolic changes in phosphorus compounds in tumours during and
after PDT by using 31P MRS. It is well-known that a drastic
decrease in adenosine triphosphate (ATP) and concomitant inor-
ganic phosphate (Pi) elevation occurs in tumours shortly after PDT
treatment with Photofrin II (Ph-II) (Ceckler et al, 1986; Naruse
et al, 1986; Chopp et al, 1987; Hilf et al, 1987; Mattiello et al,
1990; Chapman et al, 1991). A similar phenomenon occurs after
PDT with disulphonated phthalocyanine (AlS2Pc) (Bremner et al,
1994) and also with d-aminolaevulinic acid (ALA) (Hua et al,
1995). Moreover, Bremner et al (1994) have shown in their MRS
studies on real-time changes during and after PDT that this Pi
elevation starts within 15 min after PDT. Chapman et al (1991)
have shown that the ratio of the concentration of Pi to that of
b-ATP increases when the tumour hypoxic fraction increases after
PDT. These phenomena coincide with the in vitro studies of Hilf
et al in which they reported that Ph-II-induced PDT inhibits the
mitochondrial enzymes (Gibson and Hilf, 1983; Hilf et al, 1984;
Perlin et al, 1985) and the plasma membrane enzymes (Gibson
et al, 1988) leading to reduction in cellular ATP levels and loss
of viability (Hilf et al, 1986) in R3230AC mammary adenocarci-
nomas. Moreover, Chopp et al have reported that the early
metabolic response of mammary carcinoma to PDT is laser dose-
dependent with sequential measurement of 31P MRS up to
7 days after PDT (Chopp et al, 1990). The heterogeneous meta-
bolic response which induces the heterogeneous tumour response
to PDT has been shown using in vivo localized 31P MRS (Ceckler
et al, 1991). These studies suggest it is possibile to non-invasively
predict the biological outcome to treatment in the early period
after PDT by the metabolic response of the tumour. These
hypotheses, however, have not been tested with long-term obser-
vations after PDT.
The results of this study support the hypothesis that it is possible
to predict the biological outcome by the early metabolic response
of HeLa cell tumours after PDT with sequential measurements of
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Summary Magnetic resonance spectroscopy in situ was used to study changes in phosphorus 31 metabolism after photodynamic therapy
(PDT) of transplanted HeLa cell tumours. Tumours were irradiated 2 h after administration of ATX-S10 (8-formyloximethylidene-7-hydroxy-3-
ethenyl-2,7,12,18, tetramethyl-porphyrin-13,17-bispropionil aspartate), a new photosensitizer and chlorin derivative. Nuclear magnetic
resonance spectra were measured prior to illumination and 1, 3, 7, 14, 21 and 28 days after PDT on each mouse. A drastic decrease in
adenosine triphosphate (ATP) and a concomitant increase in inorganic phosphate (Pi) were evident on the first day after PDT in all cases. The
b-ATP/total phosphate (P) ratio was 0.64 ± 0.29% (average ± s.d.) in complete response, 0.67 ± 0.30% in recurrence and 2.45 ± 0.93% in
partial response. Comparison of this ratio to the histological findings revealed that the b-ATP/total P ratio reflects the HeLa cell tumours which
survived PDT. In other words, partial response on the one hand was distinguished from complete response and recurrence on the other with
this ratio 1 day after PDT (P < 0.05). In addition, the ratio of phosphomonoester (PME) to Pi rose beyond 1.0 when macroscopic recurrence
occurred, while it stayed under 1.0 in complete response. This finding suggests that the recurrence of HeLa cell tumours can be detected by
the PME/Pi ratio.
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photosensitizer and chlorine derivative developed to decrease
phototoxicity, was used in this study. Moreover, we also show that
tumour recurrence can be detected by 31P MRS monitoring.
MATERIALS AND METHODS
Animals and tumour line
Female BALB/c nude mice were supplied by Japan SLC Inc.
(Hamamatsu, Japan), and housed four per each cage and kept
under specific pathogen-free conditions. The mice were 8 weeks
old and weighed 18–21 g when the experiment started. HeLa cells
(strain; 15S3D) of 5 ´ 106 0.1 ml–1 were implanted intracuta-
neously into the right side of the back. The tumours were
measured in three orthogonal diameters (D1, D2 and D3) at 2- to
3-day intervals with a caliper before and after PDT. PDT treatment
was given 9–12 days after inoculation when the tumour was hemi-
spherical in shape and had reached the desired size, approximately
10–12 mm in D1, 7–9 mm in D2 and 4–6 mm in D3. No sponta-
neous necrosis was observed at these sizes.
Chemicals
The photosensitizing drug ATX-S10 was synthesized, purified and
provided by Toyo Hakka Kogyo Co. Ltd (Okayama, Japan). The
chemical structure is shown in Figure 1. This compound is water-
soluble and features rapid body clearance. The absorption
maximum is at 670 nm (Takemura et al, 1993). The solution of
ATX-S10 (2 mg ml-1) for injection was made by dissolving phos-
phate-buffered saline (PBS) at a pH of 7.4, and 25 mg kg-1 was
injected intraperitoneally 2 h before laser irradiation. PBS was
locally prepared by dissolving 8 g sodium chloride, 0.2 g potas-
sium chloride, 1.15 g of sodium hydrogenphosphate (Na2HPO4)
and 0.2 g of potassium dihydrogenphosphate (KH2PO4) to 1 liter
of aqueous solution and adjusting its pH to 7.4.
Fluorescence detection of ATX-S10 in the tumour
The accumulation of ATX-S10 in the tumours was detected by
fluorescence using photonic multichannel analyser 10 (PMA 10;
Hamamatsu Photonics KK, Hamamatsu, Japan). The tumours
were excited at 410 nm, and the fluorescence emission was
scanned from 300 to 800 nm, resulting in the appearance of a
distinct peak positioned at 670 nm.
PDT efficiency
An yttrium aluminum garnet-optical parametric oscillator laser
(YAG-OPO laser; Hamamatsu Photonics KK, Hamamatsu, Japan)
was used to generate light at a wavelength of 670 nm. The beam was
transmitted through a 800 mm fibre. The output energy was
5 mJ per pulse, the repetition rate was 15 Hz, the pulse width
was 5 n’s and the power density was 75 mW. Laser irradiation was
performed from 13 directions around the tumour at a distance
of 3–5 mm from the tumour surface. The duration of light exposure
was 1333 s, for a total light dose of 100 J per tumour. Mice with the
appropriate tumours were divided into four groups:
group 1 (four mice), given neither ATX-S10 nor light exposure;
group 2 (four mice), irradiated without ATX-S10 administration;
group 3 (five mice), given ATX-S10 without light exposure; group 4
(20 mice), irradiated 50 or 100 J per tumour with ATX-S10.
NMR spectroscopy
NMR spectra were obtained at 109.25 MHz for 31P on a JEOL-
GSX 270 WB spectrometer (JEOL, Tokyo, Japan) with a 9 cm
bore 6.4 Tesla vertical-type magnet. The magnetic field homo-
geneity was optimized by observing the 1H signal from the water
in the tumour. 31P MRS was obtained using a pulse width of 15 ms,
corresponding to the optimal signal. Each spectrum allowed for
512 acquisitions collected. Typical acquisition parameters for the
31P NMR spectra were as follows: 10 KHz spectral width, 2048
data point, 0.1 second acquisition time and 1.6 second repetition
time. The data were collected as a set of 13.7 min.
Phosphorus metabolism
A home-built hemispherical three-turn surface coil, with the
largest turn having a major axis of 13 mm and a minor axis of
9 mm to fit the initial tumour size, was positioned over the HeLa
cell tumour. The surface coil used in this study has a high resolu-
tion and a height/half-width ratio exceeding 100, with the signal
contribution from normal tissue adjacent to the tumour minimized
by its hemispherical shape. Therefore, spectra from larger tumours
contained very little contribution from underlying muscle, while it
was taken into consideration that those from smaller tumours may
have contained a contribution from non-tumour tissue. For the
NMR study, the mice were anaesthetized using an intraperitoneal
injection of 10% PBS solution containing 50 mg kg-1 of pentobar-
bital, which produced an anaesthetized state for about 60 min. The
mice were taped to the NMR probe, and this probe was set in the
magnet bore vertically. The measurement of 31PNMR spectra was
done just before PDT, and 1, 3, 7, 14, 21 and 28 days after PDT. A
small bottle including 25 ml of 1 mol hexamethyl phosphoric
triamide (HMPA) solution was attached to the centre of the surface
coil as an external reference. We adopted this reference halfway
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Figure 1 Chemical structure of ATX S10through this study to confirm the index of the high resolution.
Therefore, the HMPA peak is not found in every 31P NMR spec-
trum chart. The spectra were analysed as follows. The area under
each peak was calculated by approximating each peak to a trian-
gular shape after extrapolation to the baseline. Total P is the sum of
the areas of seven sharp peaks and the broad 31P component which
was generated under these sharp peaks. The b-ATP/Pi ratio and
b-ATP/total P ratio, values which represent the metabolic status of
the tissue, were calculated and compared with the various biolog-
ical outcomes. For statistical analysis, a Student’s t-test was used
to obtain a comparison of each treatment outcome. For all tests,
a two-sided P-value of less than 0.05 was considered to be a statis-
tically significant difference.
Histological study
Confirmation of the biological outcome: in the standard experi-
ment, just after the 28-day MRS measurement, the whole tumour
tissue, including underlying muscle, was removed to evaluate the
PDT effect histopathologically. Comparison of 31P MRS with the
histopathological findings: next, in order to compare 31P MRS with
the histopathological findings, we additionally prepared eight
tumours in the same fashion as group 4, and excised them on the
first day, when the biological outcome was suspected with 31P
MRS after PDT with 50–100 J laser irradiation. Detection of the
tumour recurrence: in yet another experiment, when tumour recur-
rence was predicted by 31P MRS, the small nodules were excised to
certify the recurrence histologically in three cases. The samples
fixed in 20% formaldehyde solution were dehydrated and
embedded in paraffin. Sections were cut and routinely stained with
haematoxylin and eosin.
RESULTS
31P NMR spectrum of HeLa cell tumours
A representative spectrum of HeLa cell tumours 9–13 days after
transplantation is illustrated in Figure 2(A). The tumour spectrum
is characterized by high levels of phosphocreatine (PCr), ATP
and phosphomonoester (PME). In particular, the PME/Pi ratio
exceeded 1.0 in tumours 10 mm in diameter. In experiments not
presented, the natural course of untreated HeLa cell tumours was
investigated with the multiple sampling of spectra 3–40 days after
transplantation. The spectrum obtained 8–19 days after transplan-
tation showed the same spectrum pattern. A spectrum obtained
from the 13 ´ 9 mm surface coil positioned on the back of mice
without tumours in order to know the background of the tumour is
shown in Figure 2(B). A large PCr peak with low level of PME
peaking is present, which is different from that of HeLa cell
tumours.
Biological outcome
In the present study, biological outcome after PDT was divided
into three categories. In four cases the tumours disappeared and no
regrowth appeared until 28 days after PDT (complete response,
CR), in eight cases the tumours disappeared by the 7th day, but
regrew after the 10th day (recurrence, RECUR) and the eight other
cases showed only tumour reduction (partial response, PR). This
biological outcome was histopathologically confirmed. Tumours
irradiated without ATX-S10 administration (group 2) and tumours
given ATX-S10 without light exposure (group 3) showed no
differences with the no treatment control (group 1) in tumour size
or colour. The macroscopic findings of the tumours shortly after
PDT (group 4) were as follows: RECUR showed almost the same
macroscopic change as CR within 7 days after PDT. On the 1st day
after PDT, no differences in tumour size among three categories
(PR, RECUR and CR) were noted. On the 3rd day, reduction in
tumour size in every PR was evident and remarkable shrinkage
was observed in every CR and RECUR. On the 7th day crusts were
formed in CR and RECUR and the once reduced tumour regrew in
PR.
Evaluation of the PDT effect
Evaluation in the early period after PDT with 31P NMR
Figure 3 shows the representative pre- and day 1 spectra of the
results. In the cases of CR and RECUR, a striking increase in Pi, a
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Figure 2 (A) 31P spectrum of progressing HeLa tumour. There are seven
sharp peaks. From left to right: 1, phosphomonoester (PME); 2, inorganic
phosphate (Pi); 3, phosphodiester (PDE); 4, phosphocreatine (PCr); 5, g-
ATP; 6, a-ATP; 7, b-ATP. (B) 31P spectrum obtained from a surface coil
placed over the back without tumour. Peak assignments correspond to those
described above
   
 
   
 
                                         
     
         
 drastic decrease in ATP, and a decrease in PME, phosphodiester
(PDE) and PCr were observed on the 1st day after PDT. In addi-
tion, there was a broad 31P component, presumably from cell
debris, upon which the cell spectrum is superimposed. A consider-
able amount of ATP was residual in PR, on the one hand, while the
ATP had almost disappeared in CR and RECUR, on the other
hand, in the day 1 spectrum. The PR pattern is definitely different
from that of CR and RECUR. In order to quantify this phenom-
enon, the b-ATP/Pi ratio which is used as a useful metabolic indi-
cator is plotted against the time after PDT up to the 7th day (Figure
4). There is no difference among the values of the untreated
control, the group given ATX-S10 only and the group that under-
136 M Nishiwaki et al
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Figure 3 Representative 31P spectra of respective biological outcome measured pretreatment and 1 day after PDT. Peak assignments correspond to those
described in Figure 2went laser irradiation only. A significant decrease in the 1st day
value is observed for the PDT group in which the tumours of
CR and RECUR indicate a greater decrease than that of PR
(P = 0.0170 by the Student’s t-test comparing CR vs PR,
P = 0.0115 by the Student’s t-test comparing RECUR vs PR). This
ratio remains at a low value up to the 7th day in the CR group. On
the contrary, in the case of RECUR, this ratio returns to the same
value as PR by the 7th day after treatment (P = 0.0093 by the
Student’s t-test comparing RECUR vs CR). Next, the ratio of
b-ATP to total P was plotted against the time after PDT up to the
7th day to analyse the metabolic change based on ATP hydrolysis
quantitatively (Figure 5). One day after PDT, the b-ATP/total
P ratio was 0.64 ± 0.29% (average ± s.d.) in CR, 0.67 ± 0.30% in
RECUR and 2.45 ± 0.93% in PR, which enabled us to distinguish
PR from RECUR and CR (P = 0.0008 by the Student’s t-test
comparing RECUR vs PR and P = 0.0007 CR vs PR). There was
no difference between RECUR and CR in this ratio (P = 0.8504 by
the Student’s t-test).
Comparison of 31P MRS and pathological evaluation
Figures 6 and 7 show the 31P MRS and micrograph of a highly
effective case which displayed the same pattern as CR and
RECUR 1 day after PDT, and one which displayed the same
pattern as PR, respectively. These results indicate that PR is distin-
guished from CR and RECUR by the 31P MRS 1 day after PDT.
Detection of recurrence
The representative time progression of spectra obtained from pre-
treatment up to 28 days after PDT is shown in Figures 8 and 9.
Figure 8 shows the sequential measurement in the case of CR in
which no re-increase in PME and PDE was detected up to 56 days
after PDT. Contrastingly, in the case of RECUR, a re-increase in
PME and PDE, which had maintained low levels while the tumour
was microscopically undetectable, was observed when the tumour
was detected macroscopically (Figure 9). PME/Pi ratio exceeded
1.0 in the progressive HeLa cell tumour as shown in Figure 1. We
investigated the correlation between recurrence and PME/Pi ratio
by calculation of all CR and RECUR cases (Table 1). The value of
this ratio in every CR case remains under 1.0, while in every
RECUR case this ratio rises above 1.0 when macroscopic
Evaluation of PDT with 31P MRS 137
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Figure 4 Changes in 31P metabolism occurring after PDT up to 7 days are
shown by plotting the b-ATP/Pi ratio for each group; data for the untreated
control (u), ATX-S10 only (n) and laser only (s) groups are also shown
(A). CR (n), RECUR (u), PR (s) (B). Bars (s.d.) are based on between four
and eight individual animals
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Figure 5 Showing the effect on 31P metabolism by plotting the b-ATP/total P
ratio for each group: data for the untreated control (u), ATX-S10 (n) only and
laser only (s) groups are also shown (A). CR (n), RECUR (u), PR (s) (B).
Bars (s.d.) are based on between four and eight individual animalsregrowth is detected. A follow-up study up to the 28th day after
PDT might make it possible to predict recurrence according to the
changing value of this ratio. Regrowing HeLa cell tumours were
detected in all three cases that were histologically studied when
the tumour recurrence was suspected by the 31P MRS. Figure 10
shows one of these cases.
DISCUSSION
Recent developments in NMR spectroscopy have shown convinc-
ingly that it represents a versatile technique for the examination of
several important aspects of tumour metabolic changes, not only
in untreated growth but also in various therapeutic responses
(Evanochko et al, 1982; Ng et al, 1982; Daly et al, 1987; Daly and
Cohen, 1989; Steen, 1989; Dewhirst et al, 1990; Negendank,
1992). Recognition of the initial metabolic change after PDT may
be very useful in order to understand the mechanisms of tumour
cell death based on the PDT treatment. In addition, in this study,
we succeeded in not only observing this initial response with
ATX-S10-PDT, but also in observing the changing process of
HeLa cell tumour metabolism in the four CR, the eight RECUR
and the eight PR cases by a follow-up study of 31PMRS up to
28 days after PDT.
We adopted a new photosensitizer, ATX-S10, which is a water-
soluble chlorine derivative. It has been reported that ATX-S10 has
the highest retention between 4 and 6 h, and clears rapidly after
24 h, after intravenous injection (Nakajima et al, 1993). We
measured fluorescence in the tumour using the PMA 10 prior
to this research. Peak concentration was detected 2–4 h after
intraperitoneal injection and almost diminished 24 h after injection
(unpublished data). We irradiated ‘2 h’ after administration of
ATX-S10 based on this study. Hashimoto and Sakata reported
that the PDT with 25 mg kg-1 administration of ATX-S10 and
125J cm-2 laser irradiation of human oesophageal squamous cell
carcinoma transplanted in subcutaneous tissue of nude mice had a
significant effect in observations up to 7 days after treatment
(Hashimoto and Sakata, 1994). Therefore, we chose a dose of
25 mg kg-1 ATX-S10 for administration and 100 J per tumour laser
irradiation. To investigate the appropriate laser dose prior to this
study, tumours were irradiated with 50, 75 and 100 J. Irradiation
with 50 J resulted in PR in all cases. Various results were recog-
nized in both the 75- and 100-J groups, with no differences
between these two groups. Therefore, we chose 50 and 100 J
irradiation. We considered that the varying biological outcome in
the 100-J group was due to the heterogeneous response of the
tumour against PDT, composed of the concentration and distribu-
tion of photosensitizing drug in the irradiated tissue, the incident
photon flux delivered to the tissue and the tissue oxygen concen-
tration, as shown by Ceckler et al (1991). ATX-S10–PDT with
these doses allowed us to obtain various metabolic patterns based
on the treatment outcome. We selected these doses as increasing
the efficacy was not the aim of this study. In order to increase the
138 M Nishiwaki et al
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Figure 6 Representative 31P spectrum (A) and micrograph (B) of highly
effective case on the 1st day after PDT. The b-ATP/total P ratio of this MRS is
0.002. Live HeLa cells were not observed in (B). Peak assignments in (A)
correspond to those described in Figure 2. (B), Original magnification ´ 3.3
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Figure 7 Representative 31P spectrum (A) and micrograph (B) of PR on the
1st day after PDT. The b-ATP/total P ratio of this MRS is 0.016. Live HeLa
cells were observed (arrow) in (B). Peak assignments in (A) correspond to
those described in Figure 2. (B) Original magnification ´ 3.3
Befficacy, more investigation about photosensitizer dose, laser dose
and the interval between photosensitizer administration and laser
irradiation are needed. We obtained the following important find-
ings from this study.
First, a drastic decrease in ATP and a concomitant increase in
Pi occurred shortly after PDT with ATX-S10. This finding was
similar to that of Ph-II–PDT (Ceckler et al, 1986; Naruse et al
,1986; Chopp et al, 1987; Hilf et al, 1987; Mattiello et al, 1990;
Chapman et al, 1991), AIS2Pc–PDT (Bremner et al, 1994) and
ALA–PDT (Hua et al, 1995), and this result indicates tumour
tissue hypoxia after treatment, which is supported by the morpho-
logical finding that vessel occlusions have developed in many
vessels within 1 day after ATX-S10–PDT (Hayashi et al, 1998).
Secondly, the detailed quantitative analysis of phosphorus
metabolites makes it possible to classify the effect of PDT. The
Pi-dominant pattern lasted for 3 days in all cases, with a decrease
amplitude thereafter, as was the case with the Naruse report
(Naruse et al, 1986). An ATP decrease lasted for 3 days as well. In
the PR case, ATP never disappeared, contrastingly in the RECUR
case, ATP peaks began to reappear at 3 days. In the CR case they
began to reappear after 7 days (Figure 8), when the underlying
intact region was detected because of the shrinkage of the tumour.
Thus, the ATP peaks that appear after 7 days in the case of CR are
contributed to the non-tumour region as shown in Figure 8B; the
spectral patterns of CR have changed to the muscle pattern.
Evaluation of PDT with 31P MRS 139
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Figure 8 (A) Multiple measurement of 31P spectra of a HeLa cell tumour
resulted in complete response (CR) after PDT. There was no tumour
regrowth detected until 161 days after PDT. A drastic decrease of ATPs was
observed on the 1st day and re-increase of PME and PDE was never
detected. Spectral intensities have been scaled relative to the first spectrum.
Peak assignments correspond to those described in Figure 2. (B) a, Original
day 28 spectrum, 512 data accumulations with a 30-Hz line broadening
exponential multiplication; b, same as a except a 400-Hz line broadening
exponential multiplication was used; c, difference spectrum of a minus b. This
spectrum resembled that of the normal muscle (Figure 2B)
Figure 9 Multiple measurement of 31P spectra of a HeLa tumour resulted in
recurrence (RECUR) after PDT. The day 1 spectrum is similar to that of CR.
The regrowth of small tumours (5 mm in diameter) was macroscopically
detected on the 20th day. The day 21 spectrum shows the progressing HeLa
cell tumour pattern: increased PME and PDE. Spectral intensities have been
scaled relative to the first spectrum. Peak assignments correspond to those
described in Figure 2Although we did not refer to the change in absolute value of the
metabolites in this study, the change in absolute value of ATP will
give us an important indication to evaluate the PDT effect. We are
intending to investigate the absolute value of the metabolites in the
near future by comparing the area of each peak to the area of the
HMPA, which we adopted in this study as an external reference.
Additionally, quantitative analysis of ATP was performed. We
obtained results in this study that agree with several researchers
who adopted the b-ATP/Pi ratio as a therapeutic index. Next we
focused on the ratio of the b-ATP concentration to the total phos-
phate. In this ATX-S10–PDT it was revealed that b-ATP/total
P ratio needs to decrease under 1% 1 day after PDT in order to
expect CR, as is shown in Figure 5. This means that PR is distin-
guished from RECUR and CR by the b-ATP/total P ratio. The
b-ATP/total P ratio is more sensitive than the b-ATP/Pi ratio for
evaluating the ATX-S10–PDT effect the next day. Next, 31P MRS
1 day after PDT, in which the PDT effect was predictable, was
compared with the tumour specimen. Laser doses of 50 and 100 J
were adopted intentionally in order to produce partial response
cases and highly effective cases representing CR or RECUR cases
(n = 8). In the case of PR, the residue ATP on the 1st day was
shown to be derived from the surviving HeLa cell, compared with
highly effective cases in which no live HeLa cells were observed
and ATP was diminished (Figures 6 and 7). This result proved the
b-ATP/total P ratio which indicates that the ATP concentration to
the total P in the surface coil reflects the live cell volume in the
treated HeLa cell tumour. As mentioned above, PR was distin-
guished from RECUR and CR on the 1st day by the b-ATP/total
P ratio, while there was no difference between RECUR and CR in
this ratio. As to the distinction between RECUR and CR, the
b-ATP/Pi ratio may possibly be one parameter. It became clear that
the time course response of b-ATP/Pi ratio reflects the therapeutic
‘dose’ of PDT, as Chopp suggested (Chopp et al, 1990). Moreover,
in the present study, we found that this ratio remained low for up to
7 days in the CR cases. Contrastingly, this ratio in the RECUR
cases reverted to the same level as that in the PR cases within
7 days after PDT (Figure 4). By using this parameter, RECUR may
possibly be distinguished from CR within 7 days after treatment.
The last important finding in this study was about the detection
of recurrence. It became clear, by the sequential measurement of
31P MRS up to 28 days after PDT, that the PME/Pi ratio rose
beyond 1.0 when recurrence occurred. As is shown in Table 1, this
140 M Nishiwaki et al
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Table 1 The detection of recurrence after PDT treatment based on the PME/Pi ratio
Mouse No. Pre- Day 1 Day 3 Day 7 Day 14 Day 21 Day 28 Result Tumour reappearing
G4-3 1.61 0.09 0.52 0.97 0.78 1.08a 1.14 RECUR 20
G4-4 1.14 0.18 0.55 0.79 0.91 0.77 1.65a RECUR 17
G5-1 3.12 0.03 0.28 0.84 3.08a 1.52 –d RECUR 10
G5-3b 3.33 0.05 0.15 0.50 1.38a 1.54 1.73 RECUR 21
G5-4 2.48 0.08 0.70 0.70 0.70 2.27a 1.69 RECUR 21
G11-2 1.97 0.18 0.18 0.88 1.60a 1.78 –d RECUR 10
G11-4 1.88 0.07 0.04 0.65 1.39a 1.05 –e RECUR 21
G13-3 2.28 0.14 0.77 0.75 1.36a 2.30 2.15 RECUR 10
G3-2c 1.82 0.13 0.76 0.38 0.98 0.45 –f CR
G3-3 1.21 0.18 0.53 0.12 0.81 0.80 0.65 CR
G11-3 1.78 0.07 0.26 0.38 0.80 0.78 –e CR
G18-2b 2.02 0.08 0.14 0.54 0.90 0.67 0.84 CR
aPME/Pi ratio beyond 1.0 was observed first after PDT. bATX-S10 30 mg kg-1 was administered. cLaser 75 J per tumour was irradiated.
dThis mouse was sacrificed on the 21st day for a pathological study. eThis mouse died of unknown causes on the 21st day. fThis mouse
died of unknown causes on the 24th day. CR = complete response; RECUR = recurrence.
Figure 10 Representative 31P spectrum (A) and the micrograph (B) when recurrence was suspected. In this case, tumour regrowth was macroscopically
observed on the 14th day after treatment. On that day, a small nodule was excised just after 31P MRS measurement. The PME/Pi ratio is 1.17 (beyond 1.0), and
the small HeLa cell tumours of 3 mm in diameter (T1) and of 1.5 mm in diameter (T2) were observed in the specimen. T2 was not observed macroscopically
before tumour excision. The surface coil was put on the area including both these tumours. Peak assignments in (A) correspond to those described in Figure 2.
(B) Original magnification ´ 3.3
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5ratio of G5-3 and G11-4 exceeded 1.0 prior to macroscopic detec-
tion of regrowth. This shows that it is possible to predict HeLa cell
tumour recurrence using the PME/Pi ratio. This was based on the
fact that the PME/Pi ratio was beyond 1.0 in viable HeLa cell
tumours and that this ratio was under 1.0 in the background tissue.
In all specimens excised when recurrence was suspected based on
the PME/Pi ratio, tumour regrowth was evident (Figure 10). The
case shown in Figure 10 was the smallest recurrent tumour that
was diagnosed in this study by 31P MRS. The detection of cancer
within normal tissue using the characteristics of cancers in
31P MRS has recently been studied (Ng et al, 1982; Evanochko
et al, 1982; Negendank, 1992). If the prominent metabolic charac-
teristics of various tumours are detected, it will be possible to
predict the recurrence of those tumours by detecting the character-
istics of 31P MRS like these HeLa cell tumours used in this study.
In conclusion, 31P MRS is a non-invasive and very useful
method of evaluating the effects of PDT and investigating its
mechanisms.
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